Physician profile
David Bryan
NPI 1396748604
$657.47
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $90.72 · 2021: $20.85.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $134.02 | 2019 | |
| Lupin INC. | $129.13 | 2019 | |
| Amgen INC. | $128.02 | 2019-2020 | |
| Abbvie INC. | $95.93 | 2019-2020 | |
| Roche Diagnostics Corporation | $44.11 | 2019 | |
| Amag Pharmaceuticals, INC. | $32.91 | 2019-2020 | |
| Duchesnay USA Incorporated | $25.73 | 2019 | |
| Dompe US, INC. | $20.85 | 2021 | |
| Coopersurgical, INC. | $18.66 | 2019 | |
| Daiichi Sankyo INC. | $16.35 | 2019 | |
| Therapeuticsmd, INC. | $11.76 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.